0000950170-24-014944.txt : 20240214 0000950170-24-014944.hdr.sgml : 20240214 20240214080011 ACCESSION NUMBER: 0000950170-24-014944 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240212 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 24632425 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 8-K 1 inkt-20240212.htm 8-K 8-K
0001840229false00018402292024-02-122024-02-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2024

 

 

MiNK Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40908

82-2142067

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

149 Fifth Avenue

Suite 500

 

New York, New York

 

10010

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 212 994-8250

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.00001 per share

 

INKT

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.01 Entry into a Material Definitive Agreement.

On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”). The Purchase Agreement sets forth the terms and conditions, including representations and warranties, for the Company’s issuance and sale of the Note to Agenus.

The Company may draw down on the principal amount of the Note from time to time with Agenus’s consent in any increment, either in the form of advancements or payments made by Agenus on the Company’s behalf. The Note carries an annual rate of interest rate of 2% (the “Interest Rate”) that accrues from the date funds are paid or advanced by Agenus to the Company. Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026. In the event of a qualified financing event, as described in the Note, at Agenus’s election, the Company must pay the principal amount outstanding and any unpaid interest, either in full or in the form of equity securities.

The foregoing summary of the terms of the Purchase Agreement and the Note does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement and the Note, which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosures set forth in Item 1.01 with respect to the Purchase Agreement and the Note are hereby incorporated into this Item 2.03 by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

February 14, 2024

By:

/s/ Jennifer S. Buell, Ph.D.

 

 

 

Jennifer S. Buell, Ph.D.
President and Chief Executive Officer

 

 EX-101.SCH 2 inkt-20240212.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 3 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Feb. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 12, 2024
Entity Registrant Name MiNK Therapeutics, Inc.
Entity Central Index Key 0001840229
Entity Emerging Growth Company true
Entity File Number 001-40908
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-2142067
Entity Address, Address Line One 149 Fifth Avenue
Entity Address, Address Line Two Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212
Local Phone Number 994-8250
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol INKT
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports inkt-20240212.htm inkt-20240212.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "inkt-20240212.htm": { "nsprefix": "inkt", "nsuri": "http://minktherapeutics.com/20240212", "dts": { "inline": { "local": [ "inkt-20240212.htm" ] }, "schema": { "local": [ "inkt-20240212.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_e0a66237-1a7c-4110-a326-a91f8a4b4df3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240212.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e0a66237-1a7c-4110-a326-a91f8a4b4df3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240212.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://minktherapeutics.com/20240212/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 12 0000950170-24-014944-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-014944-xbrl.zip M4$L#!!0 ( 1 3EBC"R-&4!, #.4 1 :6YK="TR,#(T,#(Q,BYH M=&WM/6E3W$BRW_=7U&-V9G $U:W[:+ W&(QG&8^!!29VWONR45*E:#VKI1X= M0+]?_S)+4E]T$,:+D0U*Y!RVG0>&8 T]!F-TZ+4J0AM/!) MG'Z^ YR* U&,P6]NP<_@1Z4M:'RSK%V=AH&@\.WT0$G^SO3(N$WCG\8][W?I/ M>CF 4C!JG\-?57SU=NL@2TM(2WZ!E-YB8?WT=JN$F[*KF+=+C7:;5O>"3(Y8 M48X2>+LU$/EEG/:8J,KLO^+!,,N1VN7N4$B2E![SAC>[6ZI7&5^UE61<#!,Q MHMD'+-V+;WK4-N3UG[&4D*H_)^S!8OEVZ\-_--O7P/)T#GK@<,LQ;2[L0'+- M-S5I>+9C"7N+I6) O4#<.TP1[=$!HI.+Y"B5%&W)+US4N3,/APM6I#E$D*,F M@^+='@ENKU!R@ATQ)<@]$K>W6P7.94)"H][U2@R3550$]@^Q9*>HQARIH8-"V7MX.CC['3-5W[7OIIM M?8@$RV3[A&HC+]^+$MX1RDJXC+;>I&P\3+D$M"UIG]M.NC.D:>DX)EQW2B:Z M*#KS(H2:B_S M%F2)G":!]T02_'%\=''XGIU?[%\??=^>'!'V='%T>'YVS_^#T[_//@ MG_O'OQZR@Y-/GX[.SX].CA582[45XF \$8=_[Y__\^CXUXN3XQWVOG/0889F M6_ZR:6UFAOBL9VD_KHR'&V%IGQ6+L")+8CD6EZ9*KK"GOK\QOK^_PV^$ZS^< MG'UBBSCX$6UO+3;N5P;01!E8O8L-.\ _$JABL60W_#I/"I>AOMS-GA\04[.SP].;M8-QT< MA-Y42IQ6>5%AX,/*C)U#2#$9TTV6Y4RWM^4;ED4,XTPJJO*XC+'-PYNP+])+ M8/MA2<6Z;UIS%"P%N6JSKASA0H$5,@65<@RCLJK$T=R W*U'IFM:!V6BJ8 $ M2<2P@%X!0Y&C)UJ'8]AZWC9]%1=Q$"?H"?=:Z 8(H>18B-K&?]Q5\2 68A0Z MWU;CDZJ9OL81\" '\;FG_N?T8O&Z;B+)6*!U-1Y?W"G(,VD725,02 MXH8'\-WC%-*,ML&N#=]S]*D?',E:V'(9KU$X01QS!A1ML^WV&00&%%"4#*X0 MD.6J&.2;WHRA7&ST#*E)"%V=ZZ;O<@(W\ON//53L DZX,ZVEN;VAZNO1MA_N>;Z/;*P7W M32WBH:'KH#LRDI3H?)X&J+-Q9W 9%Y2_+(^Q9*7V^U[DETWDI_CX([N8R@3O ML*,T[#S2)5X^X>9F>7QNYUX.7$*H[<,;@0X+S6EM@]JY9*)@YT,(*<$F69RR MH[)@!WV!)BA_\_P8XK$N\ZN&W& -N8F.K3'Q:Q=XO7>4W5W1NZ/0TK^P*XU$ MH'EXNX5:^:N[U4M5W&+[9$6N&6J:P4/'-[CE1VB?;-?AK@V>%?B&M#58C7U" MQ9_EZ#NKE;7S$CGK(*O2,A\=9'+67Z75/EH+*&&89U?4SEH=U?>0B&N1PR/\ MT\V(H!XYU9XN@L@R ZZ) %T1.XBX[T8F]W7A6Y&O.8[MKF:J/\0)8-\!Y&N< M-DW3N:7YFO?=SYLT;6GIP$/7P'D#V^.!;TKN.8XO0X%3&*YHWB[$S5&SFAGA:ASD?2ES*(KFU^]Q"OH:K:5N^>A% M1&6?[5]!6CTD0/W:4V%$EFV:EN1NY%G<$HZ!88HF.&C@ZM*PI0EB75-AK'$J MSBNLS6Q->VRP.98K8Y/E:G-5UBI4U((<[=>6$V'86N )!V-ZS^>6CLR+N.M TMLKGA MFV@KM,#EPK4=[GI@^);F6%&P6@6E8NF3_#3/KF)U7N+K)3H?.#T;[6H]>)%E MW6YE/;A-U"V^KX/I28\+B")NF;;&?1:?5JQ/<]1N\5 D[/ &PJJ,KX"=1%$<0K'6[->W MX1"]R%P?*@1&&N'.A-["'5ZOB_,O:M>I;M@O=]OI9*O/3S]XAN[N%NP"$ACV ML[1=/E";II***,;VD?9*JGI/]*:7C>,!OK.E>](W79>[PA3<,AR+"T<+> #" M,FS+<4Q??ZYC07$*X;AF5\*@DX2K#%*>0=;(<1S= . B"@TDJV9R7QH8$#H6 M!$&H@>/;SR7K[QE*UBGQU-J7='W?XAZ&MZO:[OMJ##;#&'PO!N!+)\&^%%-O MV(;6#UF. L^.U8[6G#6/3<2PP^*(=K&FER#9.>5%V.^B*)NS%ZO8U]HQ7S?_ M/Y\J8CC,LV$>TPZ5(+MA 239-;$3%1*7,8]_ M9!$J/?26XH+%U(1$-BLS5L2#*BE%"EE5)"-6B#(NHI&JV53( D2TWHK0G"W+ M)UNQ*VPG9R(=M641ZM3LFNI1_BZF;1_%4_VR%1")S7'$U+T&:A+CE#9;]+AA M*;%N=; 2I^;=W-;P1]K0&?G08;![Z\72\Q7W(KWD?(4TS$BZGLO!U- G#7UT M1VW0>> 94NB:9WGBV3[IO_.X1!+3WIXJ;7:J%+<3N4&6)8% CBB1+Y^#Z$\_ M^*YE[=[G0'TM-FO(@42=I@<;3IW5/*O0O<&8H!&9N3.:=#1S6W?9P82QJ&;CH^=VQ:!0H"9$3/TKD1:KX3"D_7#/E/,PAJYA7R9+>XX%IFO9''S:1F0X$3*WT+CI!8$> M!;8?Z=&*6?JH*"K(7QG[28QM K>VPX0P#+O.A1XUU%#W7YB1Q_+)4S>GSR=6Z%AZ(0W+M*5G/S^)4CM.(]T(E-%Y/)LL36RCEXO3 M?UYFX><=AFX0NQ))!>SO. ?XH[,A7Y%@)&* MC4SIF;[./0#?OK/G]LF;@:U+W3)M+36K< M,H3/A8@"#KKG6\+ R/KYFWY:]=K&[^H"JUN9$#*73]TCO]39P_#V6!12_%6K M8/9)Y)^A7/_>E?NOQ'P(P/Z/S NJB@+GUTKA@ M.$! VEU2ROTRSZ[+/N5UAK2&*@HF(8K3^EJK>L5(LQ=GQVN(1G[KF:FKI;DMQU?-?W=!V]1&&B&H, U1BZC1Q,H0-XKNN8P6H.1;1C M_U4-_: >^;KSNLZ]>=WOFV&.HCM4S0XJF(5Z*[ZUQ:./6@D2"$O42FFF4J)5 M 0H*T6PVDM W8F*5)JV_.D%SJ_I*1M3Y=8Q=$[>F.&PLR>$J+K >ZCJ1AK3F M*,*0KKXB8/J*CA2Y+.HM)')9/M;<%N-\[+3VZCQ#)GP0X O;Y0"&SBW/U[@G M;8^[OFV9D6Z:@6.M2"9N+L9$J^^I_?H+'6NZ$' VI;'X\R";M&UL:F4O2N"& MRSBO>8X2[M4@W6V_*D2EN[>^C_*_55'&T:CM14%QE!/":;S(TL\G;O EU"D* M+B(TICV17(M1T631'_\EECLF[;U!92Z0=I%71P#9P];LQF(J6E+NJ9N @2U4(1Y)]FF=T[U.& M0SG.T,Z<5CGJZ&)J2F8&<+MXW,FT]J^3@E2O&3&ZU$55[V5LQGOW,-"QIMK# M\>$\,2##0X:D&E(K?[<[&D.J)V1DID=(U=LQ=1@1=!%.!90%*?*R'B629U H M:N(L2:7M::OO^/!*#CC]!59LUG0)\EKD9'G1*]]1=G0*V_&!&,*:/C:G*A2B M7O0A0(7DF!C/=\R?RHI/\,LW5]YJ2&JX%Y?89_@RT+XK1="*WT",F,S%-1KT MZY32]LND:\R<$4HD*[$K8E/U6[F'$\VB&!Q[([$@>552GH:Y$K =!K&*K!M! M)I^)FA?R2C3[) IR,8=B5/\]$%(YN8UV:$8X+T\!]$42-6*MAAFB%%)@+&@ M:86XY,WG#V*E](IR_,+X<491'+7E9V*B,;!749*;FU?8:$T#K$+?(6!1E:*W M*W(DG(@EC;[!1DX-G(@U&7B'C7LI<.1)T[)2!^2E!]362&U)(++RT,0I13W' MT\;I&NT(3<04]TD8T"0MIFA5JN@'+<,.3OAEG4,:1T]5VDQ1UG9?F7T'6?FH9O7Z(QTD(NPO9./ZVO0F\D(+I(IWZMQ3$>9Q4&>?VIG% MDG)>-E4XB$RS,X/K /U>A>M]J"DF78C/1+1KQKLEY?09T7*$1K;-6[T(M^[% M&!6<9KC,5!*@&@R(FQL=4[M1S<,"KZN5**6Y988=DA)$QU%]N 95)^I#E8Z MLM:1<3$E#,AD,5H*NG8S!V0O5+KC#XVV>O>>3G<:SU0)?* .SV##E#JYZ<R]*]*?;@@&;5?V:%[4HG;=8W_:^S^_55#L3K=\DG@6)A92[KU!!'X MOB)!HZ.9[ CZ/:0DF#O5X.*GL(E'/7W)S!4)FFI.5&4_RQ%=.2]%$>*7T=INW5O;.9IOC\K=HLM^@S2- M(\C9>8?]4D&2[+#3?N=]YYM6:)MH#5YQ?<7U4;AVW,<=AU]5EFH9"99J"CIN M=YI#$Z029'[_ZVU^V7@^3=_P-02P,$ M% @ !$!.6.:I+DB\" \60 !$ !I;FMT+3(P,C0P,C$R+GAS9.U< M6W/:.!A][Z_0TI=VML:7M$W#E'38I-UAMFTR(9WM[,Y.Q]@"-#42*]L)^?U#H#8(C;"TW[GVT@9 MC"Z&P\Z'\V?O?U$4*YJAZ">W^FGOC=Y[?=I]=_I6^U73>IJ62D86#Q1-9QYX8;T$/!7+ M&V/H. _@$\(FMI#I@)'(]!488JL+!HX#;G@J%]Q %]([:'=#S*5K]]Q0@V?2 M*?2^FG/H+DP+]CN1DCG"/[T9I.8",E K%,)SU@S=Z #3\R@:^Q[\1.C\$DY, MW_'Z'1__ZYL.FB!HLW?L0/YR,@&IQZQ0L-N#V)\;<:;+,76ZA$YY1IH*EQ[$ M+AH[4.%AC$N@3C%X"8;)F9 X,7_W]R=10]#EA^=!T0Z +$^YX:%_U@K7- 41&W(Q@<42-(U_L=&C]1 $E\R,!"B@13< M>S4/DH/W76A?X?/@>D%9MX_#]_>9W8@21R$5"2W3L7SG\>D26J7)HINBN+*% M*-I:\(H=UEWE,^/);N"D@4(.NLO>C,))O\/!%8'&J_+S]8L_ O*8UG['94W* MB7J2C&YS#!W^RJ)HSK.B2PID1-UYB(X\GB"&R>8:C*,V&W.3;..,B94)=7@K M)S0K?_U>YCG[\.."L+G68.QZU+0\@110ZW>*S]5F2 U8 =G!=,0QIQ)2V><- MD;I@=67 9H07Q(:R%Y5^W! E49>O(46$56>;3U0EW.1Q#9/D'4@%M^!Q0Y3" MAC^P;=;ENM$_UA*A+N%7'MLR6>,19(U6R/(F<45OR3U>1345V0;1:\*FKLY? M:%'2MBN"VZ [8I,$>$6O*;E#X8JBDG ^O%'*%ZQI4],9LB%M^0=\*.6:CVN4 MY$>V7)TB//V=DGMO=D'F"Q.74Y5'-TMX>4M-MMKFDY:P4R]G6PQME.HGY,"O M_GP,:2G%5$BCU(;8(I2MFH*Y7]!*+HC/JN%#93=0G:I1 3=PBOC,# >64"GC M7%BC%&_-Y=!F;1M-4+@D75$7RN(;(LT7SL[UC.#R.EL(:8C:-645;G("!:#&J+'1D/^7<+H83XF,F;9YPV1 M^I,5%EOV\WKOXZCCUK+ZN XG?, _PM4/Z)K*3@Z5/SS?@!&_*-,0 'J9-MVBG8].5RHY%C M Y2)UFI=; AZ]@M#<$ 0PN^6FN"/[<7MJ7-,>KD6FHU;$@\,J0CI%?B G!, M<(5;T6+4H>7VGC2F);$JGDA)T)8)!1RR,149$^.)A(28@('6WBM5^1M/I"9 MY>4B<.O7D_- MA,2@8$ #3"X^OE+C9'M5 A($&*""+0!+07;9$LA2Y 1@-@ M_2H29V4[]AP'A$#UDZXT6+;3D8%.M?$H@X;ZK:P?LYVB! MPL/K)EQ@TVZE@ MH""+VD!MRQLY&TH(8$" TP#I59;.AB(8K&*E<$$(#$)D$$ W**L&04TIR3M# M&_(/T@(R ;KQ8OP2"-0FF*=-HPW9"R@@L&KOG(J&TJ;48R @D.KDG;&;-JTK M(08(0>ID*_6?-F0=88$LV!KL!S1KP)G4$MFSRQ4,H@C5(JQC6'A*2"9*/J%D M+MOV(K(C9?98F0/7!%7I9AE!M>B,M4E5MH4F?JEY5ZQ-HI4;:P3CN5&H*R JNL86W0^ M+$\A:](=CXD=CXD=CXG52^EX3*P1LL=C8L=C8L=C8K40/AX3>P)JQV-BQV-B MQV-BS5,_'A/;FMKQF-BF]/X?Q\32'L.3&#@+DS(\Q9HA)YYKK+FK)K>:)Y2U MYWY'US1=XS\AMV!S$EY7^QVVHO%=1H8L.&UYE=@E85E'(-:EG^RYKA);(2DX MXT $AI9$HDO;? )"KWO:NI-FX2 MG?L^%I:X/4F+?'T0 DN^UM>@0 M)J/COL_DY!9CK.]DWUNCS)],:N:^#X@Y>S.IEON^D"JQ2).2>\S,+=HEEM^) M)0+$)C(4_@YZ>/N]FOO5^^A&ZK?QPSOA+_6?_P=02P$"% ,4 " $0$Y8 MHPLC1E 3 SE $0 @ $ :6YK="TR,#(T,#(Q,BYH M=&U02P$"% ,4 " $0$Y8YJDN2+P( #Q9 $0 @ %_ J$P :6YK="TR,#(T,#(Q,BYX XML 13 inkt-20240212_htm.xml IDEA: XBRL DOCUMENT 0001840229 2024-02-12 2024-02-12 0001840229 false 8-K 2024-02-12 MiNK Therapeutics, Inc. DE 001-40908 82-2142067 149 Fifth Avenue Suite 500 New York NY 10010 212 994-8250 false false false false Common Stock, par value $0.00001 per share INKT NASDAQ true false